Please join us for a live webinar on the 27th July 15.00–16.00 at which Professor Axel Behrens (Cancer Research UK Convergence Science Centre Scientific Director) is pleased to host Dr Navita Somaiah and Professor Joshua Edel. 

In this series of webinars brought to you by the Cancer Research UK Convergence Science Centre at Imperial College London and The Institute of Cancer Research, London, researchers across the two organisations will discuss key challenges facing cancer research and opportunities for new convergence science approaches to address these. Join us to consider how novel approaches and technologies could shed light on unresolved problems in cancer biology, to innovate new ways to address challenges in cancer and bring pioneering treatments to cancer patients faster.  

 

Dr Navita Somaiah – The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust

 

‘Convergent imaging and sensing solutions for personalised radiotherapy'

 

There is a clear unmet need for the development of robust minimally invasive imaging and circulatory biomarkers in order to tailor radiotherapy based on response of both tumours and dose-limiting normal tissues. For example, early prediction of radioresistance will enable selection of patients for novel drug/immune-RT combination therapies. De-escalation strategies in patients with radiosensitive tumours will allow better sparing of late RT-related toxicities. In this talk Dr Somaiah will highlight the role of convergence science in addressing some of these problems using examples from ongoing projects investigating 3D-super resolution ultrasound, radiomic/AI analysis of MRI and nanopore-based size profiling of cell-free DNA.

 

&

 

Professor Joshua Edel – Department of Chemistry, Imperial College London

 

'Multiplexed detection of soluble proteins and other biomarkers in unprocessed clinical samples'

 

There is an enormous need for analytical methods that can achieve simultaneous detection of multiple soluble proteins and other biomarkers in complex biological fluids. A technology that can achieve this holds the promise of far-reaching impact in multiple healthcare grand challenges both in point of care diagnostics and monitoring disease progression. In this talk Professor Edel will report on a nanopore technology that can be used to detect proteins and miRNA at the single molecule level. This is achieved via synthesis of molecular probes that can be used to confirm concentration and presence of a particular biomarker. Each probe contains an aptamer sequence for the detection of protein biomarkers or other biomarkers. Detection is validated in clinical samples from patients and control groups. This technology offers great promise for the identification as diagnostic/prognostic biomarkers and validation of emerging biomarkers rapidly and with high sensitivity.

 

Registration

 

To receive information about how to access this event please email icr-imperial-convergence.centre@imperial.ac.uk

 

Please note: This webinar is exclusively available only to colleagues across the Institute of Cancer Research, Imperial College London, the Royal Marsden Hospital and Imperial College Healthcare.